Skip to main content
. Author manuscript; available in PMC: 2008 May 17.
Published in final edited form as: Drug Alcohol Depend. 2005 Sep 28;81(3):301–312. doi: 10.1016/j.drugalcdep.2005.08.002

Table 1.

Baseline demographic characteristics and substance use variables by site

Variable (percent or mean (S.D.)) Site 1 Site 2 Site 3 Site 4 Site 5 Total X2 or F
Female 42.9 28.4 42.6 66.7 10.3 43.2 48.03**
Ethnicity, European American 80 81 72 72 0 71.6 259.4**
 African American 0 6.4 20.4 0 62.1 9.8
 Latino .8 2.3 0 0 31 2.7
 Multiethnic 17.6 7.3 5.6 26.3 3.4 13.8
 Other 1.7 2.8 1.9 1.8 3.4 2.1
Employed full or part time 34 54 43 20 26.1 36.9 28.54**
Married or cohabitating 74.8 81.7 77.8 85.1 93.1 80.6 7.55
Admission prompted by legal system 57 70 46 31 91.3 53.2 47.2**
On probation or parole 35 39 30 36 82.6 37.6 22.8**
Any previous drug/alcohol treatment 60 50 62 69 87 61.7 14.38**
Principal drug used
 Alcohol 59.5 60.6 57.9 29.8 27.6 50.3 141.7**
 Cocaine .9 3.7 13.1 4.4 13.8 5.9
 Marijuana 14.7 22 22.4 14 51.7 20.2
 Opiates 4.3 4.6 4.7 5.3 6.9 4.8
 Methamphetamines 20.7 8.3 0 46.5 0 18.1
 Benzodiazepenes 0 .9 1.9 0 0 .6
Age 32.8 (10.4) 34.0 (11.2) 32.5 (9.1) 31.2 (9.0) 37.2 (8.8) 32.8 (9.9) 2.6*
Years of education 11.8 (1.8) 12.8 (2.1) 12.4 (1.9) 11.8 (1.6) 11.6 (1.6) 12.2 (1.9) 7.1**
Days of substance use, past 30 8.3 (10.3) 7.9 (8.5) 13.1 (10.4) 10.3 (9.0) 8.8 (10.0) 9.8 (9.8) 5.1**
ASI composite scores, medical .30 (.37) .25 (.34) .17 (.31) .36 (.34) .38 (.38) .27 (.34) 4.286**
Employment .76 (.25) .66 (.30) .60 (.27) .84 (.23) .11 (.11) .72 (.28) 16.73**
Alcohol .20 (.22) .17 (.18) .31 (.28) .20 (.25) .09 (.09) .21 (.23) 7.62**
Drug .10 (.10) .08 (.11) .14 (.11) .16 (.12) .07 (.07). .11 (.12) 8.07**
Legal .24 (.21) .12 (.17) .18 (.20) .22 (.24) .16 (.16) .19 (.21) 6.764**
Family .14 (.21) .15 (.21) .18 (.23) .26 (.25) .20 (.20) .18 (.22) 4.29**
Psychological .21 (.23) .23 (.22) .30 (.25) .40 (.21) .15 (.15) .27 (.22) 14.18**

Note: n's for Sites 1–4 = 100, n for Site 5 = 23. Individual sites are not identified to protect anonymity of participants and clinicians.

*

p < .05.

**

p < .01.